Opens a New Solution PathIn Ms. Liu’s case, 3 billion “trained” NK cells entered her body, likely precisely identifying and clearing cells causing inflammation and abnormal proliferation, and remodeling the immune microenvironment. They not only greatly reduced the solid nodule but also eliminated the premenstrual pain that had troubled her for years. This treatment model, based on activating the body’s own immune function, breaks the traditional binary choice of “surgery or

The application of CAR-T cell therapy provides new treatment options for patients. Clinical evidence shows that CAR-T cell therapy has achieved remarkable efficacy in hematological malignancies, with some patients even achieving complete remission. All currently approved cellular products have reported these longterm durable responses. Studies show that 83% of lymphoma patients achieve remission after receiving CAR-T cell therapy, of whom 53% achieve complete remission [2].